The United States Food and Drug Administration (USFDA) has conducted an inspection at the Cipla’s manufacturing facility in Goa, India from June 10, 2024 to June 21, 2024. On conclusion of the inspection, the company received 6 inspectional observations in Form 483. The company will work closely with the USFDA and is committed to address these comprehensively within stipulated time.
Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.
